Skip to main content

Advertisement

SpringerLink
Log in

Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study was conducted to evaluate the response rate of gemcitabine and cisplatin as second-line combination chemotherapy in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Thirty-eight eligible women with measurable disease and anthracycline- and taxane-pretreated MBC were enrolled. The chemotherapy treatment consisted of gemcitabine (1,250 mg/m2 by intravenous infusion over 30 min on days 1 and 8) and cisplatin (75 mg/m2 by intravenous infusion over 1 h on day 1), which were administered every 21 days. Thirty-seven of 38 (97.4%) of patients were assessable for response. The objective response rate was 42.1% (95% CI, 26.4–57.8%) with 16 partial responses. The median time to progression (TTP) and overall survival (OS) for all patients were 5.4 months (95% CI, 2.7–8.1 months) and 13.9 months (95% CI, 9.4–18.4 months), respectively. The most frequent hematologic-related adverse events were grade 3/4 leucopenia and thrombocytopenia, observed in 10 patients (27.0%) and 11 (29.7%), respectively. Grade 3 stomatitis was observed in 3 (8.1%) patients. No grade 4 nonhematologic toxicity was observed in this study. No treatment-related deaths occurred during the study. In conclusion, the combination of gemcitabine and cisplatin is a safe and tolerable regimen as second-line combination for patients with anthracycline- and taxane-pretreated MBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  2. Vici P, Di Lauro L, Sergi D, Foggi P, Viola G, Mottolese M, et al. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. Oncology. 2008;75:175–81.

    Article  PubMed  CAS  Google Scholar 

  3. Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist. 2001;6 S3:17–21.

    Article  Google Scholar 

  4. Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995;13:2879–85.

    PubMed  CAS  Google Scholar 

  5. Vici P, Belli F, Di Lauro L, Amodio A, Conti F, Foggi P, et al. Docetaxel in patients with anthracycline-resistant advanced breast cancer. Oncology. 2001;60:60–5.

    Article  PubMed  CAS  Google Scholar 

  6. Valero V, Hortobagyi GN. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol. 2003;21:959–62.

    Article  PubMed  Google Scholar 

  7. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy. 2009;55:155–60.

    Article  PubMed  CAS  Google Scholar 

  8. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol. 1995;13:2731–6.

    PubMed  CAS  Google Scholar 

  9. Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 2001;60:303–7.

    Article  PubMed  CAS  Google Scholar 

  10. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002;62:2–8.

    Article  PubMed  CAS  Google Scholar 

  11. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521–30.

    PubMed  CAS  Google Scholar 

  12. van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol. 1999;10:441–8.

    Article  PubMed  Google Scholar 

  13. Nagourney RA, Link JS, Blitzer JB, ForsthoV C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000;18:2245–9.

    PubMed  CAS  Google Scholar 

  14. Mohran TZ. Gemcitabine and Cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Canc Inst. 2004;16:8–14.

    PubMed  Google Scholar 

  15. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, Rauthe G. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006;57:640–6.

    Article  PubMed  CAS  Google Scholar 

  16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.

    Article  PubMed  CAS  Google Scholar 

  17. Rivera E. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. Breast J. 2010;16:252–63.

    Article  PubMed  CAS  Google Scholar 

  18. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, et al. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2005;28:195–200.

    Article  PubMed  CAS  Google Scholar 

  19. Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, et al. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol. 2007;59:269–74.

    Article  PubMed  CAS  Google Scholar 

  20. Sánchez-Escribano Morcuende R, Alés-Martínez JE, Aramburo González PM. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clin Transl Oncol. 2007;9:459–64.

    Article  PubMed  Google Scholar 

  21. Kim JH, Oh SY, Kwon HC, Lee S, Kim SH, Kim DC, et al. Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer. Cancer Res Treat. 2008;40:101–5.

    Article  PubMed  Google Scholar 

  22. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009;27:2163–9.

    Article  PubMed  CAS  Google Scholar 

  23. Bishop DK, Ear U, Bhattacharyya A, Calderone C, Beckett M, Weichselbaum RR, Shinohara A. Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem. 1998;273:21482–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to all the staff at the study centers who contributed to this study.

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Department of Breast Cancer, Hospital Affiliated to Academy Military Medical Science, No. 8, Dong Street, 100071, Fengtai District, Beijing, People’s Republic of China

    Tao Wang, Shaohua Zhang, Min Zeng, Xinyou Lu, Ge Shen, Shikai Wu, Santai Song & Zefei Jiang

Authors
  1. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaohua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinyou Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ge Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shikai Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Santai Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zefei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zefei Jiang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, T., Zhang, S., Zeng, M. et al. Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 29, 56–61 (2012). https://doi.org/10.1007/s12032-010-9814-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9814-7

Keywords

Search

Navigation